- Home
- ACRS vs KOD Comparison
ACRS vs KOD Comparison
Compare ACRS & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- KOD
- Stock Information
- Founded
- ACRS 2012
- KOD 2009
- Country
- ACRS United States
- KOD United States
- Employees
- ACRS N/A
- KOD N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACRS Health Care
- KOD Health Care
- Exchange
- ACRS Nasdaq
- KOD Nasdaq
- Market Cap
- ACRS 170.9M
- KOD 191.6M
- IPO Year
- ACRS 2015
- KOD 2018
- Fundamental
- Price
- ACRS $1.53
- KOD $2.81
- Analyst Decision
- ACRS Strong Buy
- KOD Hold
- Analyst Count
- ACRS 7
- KOD 4
- Target Price
- ACRS $11.67
- KOD $8.00
- AVG Volume (30 Days)
- ACRS 1.2M
- KOD 339.3K
- Earning Date
- ACRS 05-06-2025
- KOD 03-27-2025
- Dividend Yield
- ACRS N/A
- KOD N/A
- EPS Growth
- ACRS N/A
- KOD N/A
- EPS
- ACRS N/A
- KOD N/A
- Revenue
- ACRS $18,720,000.00
- KOD N/A
- Revenue This Year
- ACRS N/A
- KOD N/A
- Revenue Next Year
- ACRS N/A
- KOD N/A
- P/E Ratio
- ACRS N/A
- KOD N/A
- Revenue Growth
- ACRS N/A
- KOD N/A
- 52 Week Low
- ACRS $0.95
- KOD $2.19
- 52 Week High
- ACRS $5.17
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- ACRS 28.64
- KOD 29.60
- Support Level
- ACRS $1.57
- KOD $2.97
- Resistance Level
- ACRS $1.78
- KOD $3.59
- Average True Range (ATR)
- ACRS 0.10
- KOD 0.27
- MACD
- ACRS 0.02
- KOD 0.04
- Stochastic Oscillator
- ACRS 17.74
- KOD 11.07
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.